Effects of medical therapies on retinopathy progression in type 2 diabetes.
By Emily Y. Chew, W. Ambrosius, M. Davis, R. Danis, S. Gangaputra, C. Greven, L. Hubbard, Barbara A Esser, J. Lovato, Letitia H Perdue and 8 more. New England Journal of Medicine, 2010
1,208 citations recorded by the source corpus.
Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/9a607a3bfd9432a917f703d573fdaa1052647711
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss (2015, background): “2 %, respectively) by at least 3 steps at 4 years [107].”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, positive): “Fenofibrate reduces the progression of diabetic retinopathy.(413,414)”
- Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. (2017, background): “However, recent studies have demonstrated that more intensive blood pressure control does not confer additional benefits on retinopathy progression compared with standard control (22).”
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, intensive glycemic control significantly reduced the risk and/ or progression of retinopathy, nephropathy, and neuropathy (73,74).”
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, positive): “Fenofibrate reduces the progression of diabetic retinopathy.(517,518)”